Frank Rimerman Advisors LLC Buys 103,035 Shares of Axon Enterprise, Inc $AXON

Frank Rimerman Advisors LLC lifted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 19,294.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,569 shares of the biotechnology company’s stock after purchasing an additional 103,035 shares during the quarter. Axon Enterprise comprises 2.4% of Frank Rimerman Advisors LLC’s investment portfolio, making the stock its 7th biggest holding. Frank Rimerman Advisors LLC’s holdings in Axon Enterprise were worth $43,760,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Keating Financial Advisory Services Inc. bought a new stake in Axon Enterprise in the 2nd quarter valued at about $31,000. Wealth Enhancement Trust Services Inc. acquired a new position in Axon Enterprise during the 3rd quarter worth approximately $33,000. Washington Trust Advisors Inc. boosted its holdings in Axon Enterprise by 1,300.0% in the second quarter. Washington Trust Advisors Inc. now owns 70 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 65 shares in the last quarter. Delos Wealth Advisors LLC bought a new position in Axon Enterprise in the second quarter worth approximately $45,000. Finally, Owl Creek Wealth Partners LLC boosted its holdings in Axon Enterprise by 84.8% in the second quarter. Owl Creek Wealth Partners LLC now owns 85 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 39 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling

In other Axon Enterprise news, insider Isaiah Fields sold 1,017 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $480.45, for a total transaction of $488,617.65. Following the completion of the sale, the insider directly owned 56,264 shares of the company’s stock, valued at approximately $27,032,038.80. The trade was a 1.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Smith sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $508.99, for a total value of $5,089,900.00. Following the sale, the chief executive officer directly owned 3,118,012 shares of the company’s stock, valued at $1,587,036,927.88. This represents a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 47,397 shares of company stock worth $26,722,984 over the last 90 days. Company insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

AXON has been the subject of a number of research reports. Zacks Research raised Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 5th. Citigroup reaffirmed a “market outperform” rating on shares of Axon Enterprise in a research report on Thursday, September 17th. Needham & Company LLC reiterated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, September 2nd. The Goldman Sachs Group reiterated a “buy” rating and issued a $715.00 target price on shares of Axon Enterprise in a report on Thursday, August 6th. Finally, Barclays lifted their price target on shares of Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $718.47.

Axon Enterprise Trading Down 6.4%

NASDAQ:AXON opened at $390.29 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80. The firm has a 50-day moving average of $501.59 and a 200-day moving average of $474.43. The company has a market cap of $31.71 billion, a PE ratio of 161.95, a PEG ratio of 7.34 and a beta of 1.44. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $764.02.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The company had revenue of $904.39 million for the quarter, compared to analyst estimates of $876.42 million. During the same quarter in the prior year, the business posted $2.12 EPS. The firm’s revenue was up 35.3% compared to the same quarter last year. As a group, equities research analysts expect that Axon Enterprise, Inc will post 2.12 EPS for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and connected systems for public safety and law enforcement agencies. Its product portfolio includes TASER conducted energy weapons, body-worn cameras, in-car cameras and other recording devices designed to support safer interactions, improve accountability and document incidents.

The company also provides cloud-based software for managing digital evidence, reports, records and agency operations. Its Axon platform connects hardware with services such as evidence management, real-time operations, computer-aided dispatch and other workflow tools, enabling agencies to store, organize and share information across their organizations.

Founded in 1993 as AIR TASER by Rick Smith and Tom Smith, the company later operated as TASER International before adopting the name Axon Enterprise in 2017.